GO:0008080 N-acetyltransferase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0008080 N-acetyltransferase activity is a molecular function defined as the catalysis of acetyl group transfer to a nitrogen atom on an acceptor molecule.
• The reaction is central to drug metabolism, xenobiotic detoxification, and post-translational modification of proteins [1,3].
• Human arylamine N-acetyltransferases NAT1 and NAT2 are classic examples, with common genetic polymorphisms that alter enzyme activity and drug response [3,5].
• NAT2 acetylation status (rapid, intermediate, slow) affects drugs such as isoniazid, hydralazine, dapsone, and sulfamethoxazole [4,5,6].
• N-acetyltransferase activity is also modulated by cellular factors such as Sirtuin 1 and metabolic states like obesity [7,8].
• CRISPR-based knockout, point mutation, knock-in, and overexpression models enable causal dissection of N-acetyltransferase function in disease and pharmacology [1,3].
Description
N-acetyltransferase activity (GO:0008080) is a fundamental molecular function that transfers an acetyl group to a nitrogen atom on an acceptor molecule. This activity is essential for the metabolism of numerous drugs and environmental xenobiotics, and it also participates in the post-translational modification of proteins [1,3]. In humans, the arylamine N-acetyltransferases NAT1 and NAT2 are the best-characterized enzymes carrying this activity, and their genetic polymorphisms are a major source of interindividual variability in drug response and toxicity [3,5]. Researchers study N-acetyltransferase activity to understand pharmacokinetics, chemical carcinogenesis, and the mechanisms of idiosyncratic adverse drug reactions [1,6]. The activity is also relevant to endogenous metabolism and has been linked to metabolic conditions such as obesity. Because of its clinical and toxicological importance, N-acetyltransferase activity is a frequent target for functional genomics and CRISPR-based modeling [1,3].
N-acetyltransferase activity At A Glance
| GO ID | GO:0008080 |
|---|---|
| GO term | N-acetyltransferase activity |
| Ontology | molecular_function |
| Synonym | none |
| Definition | Catalysis of the transfer of an acetyl group to a nitrogen atom on the acceptor molecule. |
| Major function | Acetylation of nitrogen-containing substrates, including drugs, xenobiotics, and proteins. |
| Representative enzymes | NAT1, NAT2, and other N-acetyltransferases. |
| Biological context | Drug metabolism, xenobiotic detoxification, protein modification. |
| Clinical relevance | Polymorphisms affect drug efficacy and toxicity; linked to adverse drug reactions. |
What Is GO:0008080?
According to the Gene Ontology, N-acetyltransferase activity (GO:0008080) is the catalysis of the transfer of an acetyl group to a nitrogen atom on the acceptor molecule. In practice, this means an enzyme binds acetyl-coenzyme A (or another acetyl donor) and transfers the acetyl moiety to a nitrogen-containing substrate, such as an arylamine, hydrazine, or the N-terminal amino group of a protein. This reaction can modify small molecules, drugs, and proteins, thereby altering their chemical properties, biological activity, or stability.
Why Is N-acetyltransferase activity Important in Cell Biology?
N-acetyltransferase activity is critically important because it determines the fate of many therapeutic drugs and environmental chemicals, and its genetic variability can lead to severe adverse reactions or therapeutic failure [1,3]. For example, slow acetylator phenotypes of NAT2 are associated with increased risk of hydralazine-induced lupus and dapsone-induced agranulocytosis, while rapid acetylators may have altered efficacy of certain drugs [4,6]. Beyond drug metabolism, N-acetyltransferase activity contributes to protein N-terminal acetylation and other cellular processes, influencing protein stability and interactions. Understanding this activity is therefore essential for personalized medicine, toxicology, and fundamental cell biology [3,5].
• Determines metabolic activation or detoxification of arylamine and hydrazine drugs.
• Genetic polymorphisms in NAT1 and NAT2 cause interindividual differences in acetylation capacity.
• Slow acetylator status is a risk factor for hydralazine-induced lupus and dapsone-induced agranulocytosis [4,6].
• NAT2 activity in bronchial epithelial cells may influence local drug and carcinogen metabolism.
• N-acetylation of sulfamethoxazole varies widely and can affect hypersensitivity risk.
• Sirtuin 1 modulates NAT2 activity in peripheral blood mononuclear cells, linking acetylation to cellular redox and aging.
• Obesity alters xanthine oxidase and N-acetyltransferase activity, suggesting metabolic regulation.
• N-acetyltransferase activity is a target for genotype-guided dosing of drugs like hydralazine.
• The activity is relevant to chemical carcinogenesis because acetylation can activate or deactivate carcinogens.
• CRISPR models allow causal testing of NAT variants in isogenic backgrounds [1,3].
Molecular Mechanism of N-acetyltransferase activity
Acetyl Group Transfer
In simple terms: The enzyme takes an acetyl group from a donor and attaches it to a nitrogen atom on another molecule.
N-acetyltransferases catalyze the transfer of an acetyl group from acetyl-coenzyme A to a nitrogen atom on an acceptor substrate, such as an arylamine or hydrazine. This reaction typically follows a ping-pong bi-bi mechanism, where the acetyl group is first transferred to a cysteine residue in the enzyme's active site, then to the substrate. The result is an N-acetylated product and coenzyme A. This activity is central to the metabolism of drugs like isoniazid, sulfamethoxazole, and dapsone [5,6].
Substrate Specificity and Polymorphism
In simple terms: Different forms of the enzyme prefer different targets, and common genetic changes alter how well they work.
Human NAT1 and NAT2 have overlapping but distinct substrate specificities. NAT2 is primarily hepatic and metabolizes many arylamine drugs, while NAT1 is more ubiquitous and acetylates p-aminosalicylic acid and other substrates. Common single-nucleotide polymorphisms in NAT2 define rapid, intermediate, and slow acetylator phenotypes, which significantly affect drug clearance and toxicity [3,5]. For example, slow acetylators have higher plasma levels of hydralazine and are at greater risk of drug-induced lupus.
Cofactors and Cellular Context
In simple terms: The reaction needs acetyl-CoA as a donor, and the cell's metabolic state can influence how active the enzyme is.
Acetyl-coenzyme A serves as the acetyl donor for N-acetyltransferase reactions. Cellular levels of acetyl-CoA and the redox state can influence enzyme activity. In peripheral blood mononuclear cells, NAT2 activity is modulated by Sirtuin 1, a NAD+-dependent deacetylase, suggesting crosstalk between acetylation and cellular metabolism. Additionally, obesity has been associated with altered xanthine oxidase and N-acetyltransferase activity in children, indicating that systemic metabolic status can affect this function.
Protein N-terminal Acetylation
In simple terms: Some N-acetyltransferases modify the starting end of proteins, affecting their stability and interactions.
Beyond small molecules, N-acetyltransferase activity includes the N-terminal acetylation of proteins, where the alpha-amino group of the first amino acid is acetylated. This modification is catalyzed by a different class of N-acetyltransferases (NATs) and is one of the most common protein modifications in eukaryotes. It can influence protein half-life, subcellular localization, and complex formation. However, the specific human enzymes and their roles are still being characterized.
Key Genes Involved in GO:0008080 N-acetyltransferase activity
The following genes encode enzymes with N-acetyltransferase activity or are directly involved in its regulation and clinical impact.
| Gene | Major Role | Research Relevance |
|---|---|---|
| NAT1 | Arylamine N-acetyltransferase 1; acetylates p-aminosalicylic acid and other substrates | Polymorphisms affect drug metabolism and cancer risk |
| NAT2 | Arylamine N-acetyltransferase 2; hepatic metabolism of many drugs | Classic slow/rapid acetylator phenotypes; drug toxicity [3,5] |
| NAT10 | N-acetyltransferase 10; involved in RNA acetylation | Emerging role in RNA modification and cancer |
| NAA10 | N-alpha-acetyltransferase 10; N-terminal protein acetylation | Essential for protein stability and development |
| NAA15 | N-alpha-acetyltransferase 15; component of NatA complex | Protein N-terminal acetylation |
| NAA20 | N-alpha-acetyltransferase 20; component of NatB complex | Protein N-terminal acetylation |
| NAA30 | N-alpha-acetyltransferase 30; component of NatC complex | Protein N-terminal acetylation |
| NAA35 | N-alpha-acetyltransferase 35; component of NatC complex | Protein N-terminal acetylation |
| NAA50 | N-alpha-acetyltransferase 50; component of NatE complex | Protein N-terminal acetylation |
| SIRT1 | Sirtuin 1; deacetylase that modulates NAT2 activity | Regulates NAT2 in PBMCs; links metabolism to acetylation |
| XDH | Xanthine oxidase; not an N-acetyltransferase but co-regulated in obesity | Altered alongside NAT activity in obese children |
| GSTM1 | Glutathione S-transferase M1; phase II enzyme often studied with NATs | Combined polymorphisms affect drug metabolism |
| GSTT1 | Glutathione S-transferase T1; phase II enzyme | Co-inherited with NAT polymorphisms |
| CYP2E1 | Cytochrome P450 2E1; phase I enzyme | Interacts with NAT2 in drug metabolism |
| ABCB1 | P-glycoprotein transporter; affects drug availability | Modifies impact of NAT polymorphisms |
| NQO1 | NAD(P)H quinone dehydrogenase 1; phase II enzyme | Studied with NATs in xenobiotic metabolism |
| EPHX1 | Epoxide hydrolase 1; phase II enzyme | Co-analyzed with NATs in pharmacogenetics |
How Is N-acetyltransferase activity Regulated?
N-acetyltransferase activity is regulated at multiple levels. Genetically, polymorphisms in NAT1 and NAT2 determine intrinsic enzyme activity, with slow, intermediate, and rapid acetylator phenotypes. Environmentally, exposure to substrates can induce or inhibit activity, and co-administration of drugs may compete for the same enzyme. At the cellular level, NAT2 activity in peripheral blood mononuclear cells is modulated by Sirtuin 1, suggesting post-translational regulation through acetylation/deacetylation. Metabolic states such as obesity have been associated with altered N-acetyltransferase activity, possibly through changes in cofactor availability or hormonal signals. Additionally, ontogeny and tissue-specific expression influence overall acetylation capacity.
N-acetyltransferase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| NAT2 | Hydralazine-induced lupus, dapsone-induced agranulocytosis | Knockout or point-mutation in hepatocytes or PBMCs [4,6] |
| NAT1 | Bladder cancer susceptibility, drug metabolism | Overexpression in bladder epithelial cells |
| NAT2 | Sulfamethoxazole hypersensitivity | Knock-in of slow acetylator alleles in immune cells |
| SIRT1 | Modulation of NAT2 activity in PBMCs | Knockout or overexpression in PBMCs |
| XDH | Obesity-related metabolic changes | Knockout in adipocytes or hepatocytes |
Drug-Induced Adverse Reactions
Slow acetylator genotypes of NAT2 are associated with increased risk of hydralazine-induced lupus and dapsone-induced agranulocytosis [4,6]. These reactions occur because reduced acetylation leads to accumulation of parent drugs or reactive metabolites. Genotype-guided dosing of hydralazine has been proposed to mitigate these risks. Similarly, sulfamethoxazole N-acetylation varies widely and may contribute to hypersensitivity reactions.
Cancer Susceptibility
NAT1 and NAT2 polymorphisms have been extensively studied in relation to cancer risk, particularly bladder and colorectal cancers, because acetylation can activate or detoxify carcinogenic arylamines [1,3]. The balance between activation and detoxification depends on the specific substrate and tissue expression. For example, NAT2 expression in bronchial epithelial cells may influence local carcinogen metabolism.
Metabolic and Inflammatory Conditions
Altered N-acetyltransferase activity has been observed in obese children, alongside changes in xanthine oxidase, suggesting a link between metabolic status and drug-metabolizing enzyme activity. Sirtuin 1 modulation of NAT2 in immune cells may also connect acetylation capacity to inflammatory and aging processes.
From N-acetyltransferase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of NAT2 increase drug toxicity? | NAT2 knockout cell line (e.g., HepG2) |
| Does a specific NAT2 polymorphism alter enzyme kinetics? | Point-mutation knock-in of slow acetylator allele |
| Can NAT1 overexpression protect against carcinogens? | NAT1 overexpression in epithelial cells |
| How does SIRT1 regulate NAT2 activity? | SIRT1 knockout or overexpression in PBMCs |
| Does obesity alter NAT activity? | Diet-induced obesity mouse model or patient-derived cells |
| Can genotype-guided dosing improve hydralazine safety? | Patient-derived iPSC hepatocytes with different NAT2 genotypes |
How to Study the N-acetyltransferase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| HPLC-based acetylation assay | Enzyme activity and kinetics | Determining acetylator phenotype in cell lysates |
| Genotyping (PCR-RFLP, TaqMan) | NAT1/NAT2 alleles | Pharmacogenetic screening |
| CRISPR-Cas9 knockout | Loss of gene function | Causal testing of NAT2 in drug toxicity |
| CRISPR knock-in | Specific point mutations | Modeling slow acetylator alleles |
| qRT-PCR | mRNA expression levels | Tissue-specific expression analysis |
| Western blot | Protein expression and modification | Validating knockout or overexpression |
| Sirtuin activity assay | Deacetylase activity | Studying SIRT1 modulation of NAT2 |
| Metabolomics | Global metabolite changes | Assessing impact of NAT polymorphisms |
Enzyme Activity Assays
N-acetyltransferase activity is commonly measured using colorimetric or HPLC-based assays that detect the formation of N-acetylated products from substrates such as p-aminosalicylic acid or sulfamethoxazole [3,5]. These assays can be performed in cell lysates or with recombinant enzymes to determine kinetic parameters and the impact of polymorphisms.
Genotyping and Pharmacogenomics
Genotyping of NAT1 and NAT2 alleles is essential to classify acetylator status. Methods include PCR-RFLP, TaqMan assays, and next-generation sequencing. Genotype-guided therapy studies use these data to individualize drug dosing, as demonstrated for hydralazine.
CRISPR-Cas9 Genome Editing
CRISPR-Cas9 allows precise knockout, point mutation, or knock-in of NAT genes in cell lines and primary cells. These models enable causal testing of specific variants in isogenic backgrounds, eliminating confounding from other polymorphisms [1,3]. For example, knocking in a slow acetylator allele into a rapid acetylator cell line can directly measure its effect on drug metabolism.
Expression and Modulation Studies
Quantitative PCR and Western blotting are used to measure NAT1 and NAT2 expression levels in tissues and cells. Modulation by Sirtuin 1 can be studied using SIRT1 inhibitors or activators, or by CRISPR-mediated SIRT1 knockout. Metabolic status effects can be modeled in obese mouse models or patient samples.
How CRISPR Can Be Used to Study GO:0008080 N-acetyltransferase activity
Knockout
CRISPR-Cas9 knockout of NAT1 or NAT2 in cell lines such as HepG2 or primary hepatocytes creates null backgrounds to study the consequences of loss of N-acetyltransferase activity on drug metabolism and toxicity. These models help distinguish the roles of NAT1 versus NAT2 in acetylating specific substrates.
Point Mutation
Introducing single-nucleotide polymorphisms that define slow acetylator alleles (e.g., NAT2*5, NAT2*6) via CRISPR base editing or homology-directed repair allows precise measurement of their impact on enzyme kinetics and drug response [3,5]. Such isogenic models eliminate confounding from other genetic variants.
Knock-in
Knock-in of human NAT2 variants into mouse models or cell lines can recapitulate human acetylator phenotypes. This is particularly useful for studying drug-induced adverse reactions like hydralazine-induced lupus or dapsone-induced agranulocytosis in a controlled genetic background [4,6].
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of NAT1 or NAT2 can model rapid acetylator phenotypes and test whether increased acetylation protects against or exacerbates toxicity. Overexpression in bronchial epithelial cells has been used to study local carcinogen metabolism.
How EDITGENE Supports N-acetyltransferase activity Research
Researchers studying N-acetyltransferase activity-related genes often need to determine whether a candidate gene is causally involved in drug metabolism, toxicity, or disease susceptibility. EDITGENE provides a comprehensive suite of CRISPR-based services to create precisely engineered cell models that answer these questions.
Contact EDITGENE today to design your custom CRISPR model for N-acetyltransferase activity research.
Frequently Asked Questions About N-acetyltransferase activity
What is N-acetyltransferase activity?
N-acetyltransferase activity (GO:0008080) is the catalysis of the transfer of an acetyl group to a nitrogen atom on an acceptor molecule, as defined by the Gene Ontology.
What genes are involved in N-acetyltransferase activity?
Key genes include NAT1, NAT2, NAT10, and the NAA series (NAA10, NAA15, NAA20, etc.) that encode enzymes with this activity [1,3].
How does N-acetyltransferase activity affect drug metabolism?
It acetylates drugs such as isoniazid, hydralazine, dapsone, and sulfamethoxazole, influencing their clearance and toxicity [3,5,6].
What are slow and rapid acetylator phenotypes?
These are common NAT2 polymorphisms that result in reduced or increased enzyme activity, affecting drug levels and risk of adverse reactions [3,4].
Which diseases are linked to N-acetyltransferase activity?
Slow acetylation is linked to hydralazine-induced lupus, dapsone-induced agranulocytosis, and some cancers, while altered activity is seen in obesity [4,6,8].
How is N-acetyltransferase activity measured?
It is measured using enzyme assays with substrates like p-aminosalicylic acid or sulfamethoxazole, often coupled with HPLC detection [3,5].
Can CRISPR be used to study N-acetyltransferase activity?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models allow precise functional studies of NAT genes [1,3].
What is the role of Sirtuin 1 in N-acetyltransferase activity?
Sirtuin 1 modulates NAT2 activity in peripheral blood mononuclear cells, linking acetylation to cellular metabolism.
Does obesity affect N-acetyltransferase activity?
Yes, obese children show altered xanthine oxidase and N-acetyltransferase activity, suggesting metabolic regulation.
What cell models are available for N-acetyltransferase research?
Common models include HepG2, primary hepatocytes, bronchial epithelial cells, and PBMCs, which can be engineered with CRISPR [2,7].
Conclusion
N-acetyltransferase activity (GO:0008080) is a pivotal molecular function in drug metabolism, xenobiotic detoxification, and protein modification. Its genetic variability, particularly in NAT1 and NAT2, has profound implications for personalized medicine and toxicology [1,3]. Understanding its mechanisms and regulation can improve drug safety and cancer risk assessment [4,6]. CRISPR-based models are powerful tools to dissect the causal roles of specific variants and to develop genotype-guided therapeutic strategies [1,5].
References
- 1. Mitchell SC. 2020. N-acetyltransferase: the practical consequences of polymorphic activity in man.. Xenobiotica 50(1):77-91 PMID: 31092097
- 2. Wise JTF et al.. 2022. Expression of arylamine N-acetyltransferase 2 activity in immortalized human bronchial epithelial cells.. Toxicol Appl Pharmacol 442:115993 PMID: 35353990
- 3. Walker K et al.. 2009. Genetic polymorphism in N-Acetyltransferase (NAT): Population distribution of NAT1 and NAT2 activity.. J Toxicol Environ Health B Crit Rev 12(5-6):440-72 PMID: 20183529
- 4. Collins KS et al.. 2020. Genotype-Guided Hydralazine Therapy.. Am J Nephrol 51(10):764-776 PMID: 32927458
- 5. Lanphier RM et al.. 2025. N-acetyltransferase (NAT) 1 and NAT2 enzyme activities drive interindividual variability in sulfamethoxazole N-acetylation.. Drug Metab Dispos 53(12):100195 PMID: 41344065
- 6. Potočnjak I et al.. 2017. Dapsone-induced agranulocytosis-possible involvement of low-activity N-acetyltransferase 2.. Fundam Clin Pharmacol 31(5):580-586 PMID: 28322460
- 7. Salazar-González RA et al.. 2018. Expression and genotype-dependent catalytic activity of N-acetyltransferase 2 (NAT2) in human peripheral blood mononuclear cells and its modulation by Sirtuin 1.. Biochem Pharmacol 156:340-347 PMID: 30149019
- 8. Chiney MS et al.. 2011. Altered xanthine oxidase and N-acetyltransferase activity in obese children.. Br J Clin Pharmacol 72(1):109-15 PMID: 21382071
